Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model
Our on-chip NAFLD model successfully recapitulated key pathological features of hepatic steatosis and functional impairment. Using this model, we evaluated TMSC-Exo and demonstrated its significant therapeutic efficacy against NAFLD.
Authors
- Qing Peng (ORCID: https://orcid.org/0000-0002-2238-8400)
- S. Kevin Zhou (ORCID: https://orcid.org/0000-0002-6881-4444)
- Y. J. Li
- Wei Fang (ORCID: https://orcid.org/0000-0003-4462-0562)
- Kexin Wang (ORCID: https://orcid.org/0000-0002-8541-7512)
- Shujiao He
- Binghui Li
- Juan Du
- Shao Li
- Nan Wang
- Ying Zhang
- Yi Gao
- Fen Yao
- Xinyi Wei
Institutions
- Shantou University (CN)
- Longgang Central Hospital (CN)
- Chinese University of Hong Kong, Shenzhen (CN)
- Shantou University Medical College (CN)
- Zhujiang Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- Shenzhen Second People's Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Journal of Translational Internal Medicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1515/jtim-2026-0007
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00